A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: Pharmacokinetics and associated outcomes

Journal of Critical Care

Volumn 18, Issue 2, 2003, Pages 107-113

  Bacopoulou, Flora ^b   Markantonis, Sophia L ^a   Pavlou, Elias ^b   Adamidou, Maria ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; CLINDAMYCIN; IMIPENEM; MEROPENEM; PEFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CREATININE CLEARANCE; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG RESPONSE; FEMALE; HOSPITAL INFECTION; HUMAN; INDIVIDUALIZATION; INTENSIVE CARE UNIT; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; OTOTOXICITY; OUTCOMES RESEARCH; PROSPECTIVE STUDY;

EID: 0037973665     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1053/jcrc.2003.50003     Document Type: Article

References (22)

1. Fisman DN, Kaye KM: Once-daily dosing of aminoglycoside antibiotics. Infect Dis Clin North Am 14:475-487, 2000
2. Giuliano RA, Verpooten GA, Verbist L, et al: In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 236:470, 1986
3. Barclay ML, Kirkpatrick CM, Begg EJ: Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet 36:89-98, 1999
4. Ferriols-Lisart R, Alos-Alminana M: Effectiveness and safety of once-daily aminoglycosides: A meta-analysis. Am J Health Syst Pharm 53:1141-1150, 1996
5. Beaucaire G, Leroy O, Beuscart C, et al: Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother 27:91-103, 1991
6. Marik PE, Lipman J, Kobilski S, et al: A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 28:753-764, 1991
7. Fayed DF, Dahmash NS, Al-Zeer AH, et al: Efficacy and safety of once-daily amikacin in combination with ceftazidime in critically ill adults with severe gram-negative infections. J Chemotherapy 8:457-464, 1996
8. Bressolle F, Gouby A, Martinez JM, et al: Population pharmacokinetics of amikacin in critically ill patients. Antimicrob Agents Chemother 40:1682-1689, 1996
9. Hustinx WNM, Hoepelman IM: Aminoglycoside dosage regimens: Is once a day enough? Clin Pharmacokinet 25:427-432, 1993
10. National Drug Association: National Formulary Guidelines, Pharmetrica A.E. Athens, Greece, National Drug Organisation, 2000, p 280
11. Prins JM, Weverling GJ, de Blok K, et al: Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother 40:2494-2499, 1996
12. Lortholary O, Tod M, Cohen Y, et al: Aminoglycosides. Med Clin North Am 79:761-787, 1995
13. Nordstrom L, Ringberg H, Cronberg S, et al: Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity. J Antimicrob Chemother 25:159-173, 1990
14. Firsov AA, Nasonov VN: Correlations between aminoglycoside pharmacokinetic parameters and patient's factors: From statement to implication for individual dosage design. Eur J Drug Metab Pharmocokinet 3:327-331, 1991
15. Lugo G, Castaneda-Hernandez G: Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med 25:806-811, 1997
16. Marik PE: Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anesth Intensive Care 21:172-173, 1993
17. Reed RL 2nd, Wu AH, Miller-Crotchett P, et al: Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients. J Trauma 29:1462-1470, 1989
18. Marik PE, Havlik I, Monteagudo FSE, et al: The pharmacokinetics of amikacin in critically ill adult and paediatric patients: Comparison of once- versus twice-daily dosing regimens. J Antimicrob Chemother 27:81-89, 1991
19. Mitchell MD, Wilson J, Dodek P, et al: Volume distribution in patients with gram-negative sepsis in the ICU. Anesthesiology 67:A126, 1987
20. Sumner WR, Michael JR, Lipsky JJ: Initial aminoglycosides levels in the critically ill. Crit Care Med 11:948-950, 1983
21. Triginer C, Izquierdo I, Fernandez R, et al: Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 16:303-306, 1990
22. Bergmans D, Bonten M: Colonization and infection with pseudomonas aeruginosa in intensive care: Endogenous or exogenous origin? Yearbook of Intensive Care and Emergency Medicine. Heidelberg, Springer Verlag, 1999, pp 131-140